Testing focused ultrasound plus Avastin for recurrent glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your glioblastoma has come back after radiation and temozolomide chemotherapy.
- You have not been treated with Avastin (bevacizumab) or similar drugs before.
- Your tumor is a single mass and can be safely reached by focused ultrasound, at least 1 cm below the skull.
- You are generally healthy enough for treatment, with good kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a focused ultrasound system (NaviFUS) to the drug bevacizumab can help people whose glioblastoma has come back. The treatment aims to deliver the drug more precisely to the brain tumor and potentially improve outcomes.
This trial studies sintilimab (an immune checkpoint medicine) plus low-dose bevacizumab (Avastin) in people with glioblastoma whose cancer has come back. It may help slow recurrence and improve outcomes by boosting the immune system while also limiting tumor blood supply.
This trial tests a combination of two drugs—APG-157 (an oral plant-based medicine) and bevacizumab (Avastin)—for people with recurrent high-grade brain tumors that have already been treated with standard therapies. The goal is to see if adding APG-157 can help control the tumor better.
This trial tests whether using focused ultrasound to help adjust the immune system can improve outcomes for people with newly diagnosed glioblastoma. You’d already complete standard brain radiation (with or without temozolomide), then undergo an ultrasound-based immune modulation approach.
This trial tests a combination of focused ultrasound and the immunotherapy drug pembrolizumab for people whose glioblastoma has returned after standard treatment. The ultrasound may help the drug work better by temporarily opening the blood-brain barrier.
This Phase 2 study tests a protective approach using bevacizumab (a medicine that blocks VEGF) while doctors carefully increase the dose in people with glioblastoma. It’s meant to help control tumor growth and possibly reduce certain risks that can happen with blood-vessel–targeting treatments.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.